AN2 Therapeutics to Meet With FDA on Epetraborole Development Path

By MarketWatch | Nov 13, 2024 at 05:06 PM EST

AN2 Therapeutics plans to discuss the development path for epetraborole with the FDA for treating non-tuberculous mycobacterial lung disease. The company aims to seek an End-of-Phase 2 meeting and align on a statistical analysis plan for patients.

Did you find this insightful?

Bad

Just Okay

Amazing

We are preparing, please wait

New Alert

Select an alert type

Sentiment Spike

Send email alert if news sentiment changes significantly

Mentions Spike

Send email alert if has a surge in mentions

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.